Benzinga - by Benzinga Insights, Benzinga Staff Writer.
DOUG IIEKKING, Chief Financial Officer at Usana Health Sciences (NYSE:USNA), disclosed an insider sell on May 7, according to a recent SEC filing.
What Happened: According to a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday, IIEKKING sold 5,198 shares of Usana Health Sciences. The total transaction value is $232,676.
Tracking the Wednesday's morning session, Usana Health Sciences shares are trading at $44.74, showing a down of 0.0%.
Get to Know Usana Health Sciences Better Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe.
A Deep Dive into Usana Health Sciences's Financials Revenue Growth: Usana Health Sciences displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 3.04%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Interpreting Earnings Metrics:
- Gross Margin: With a high gross margin of 81.09%, the company demonstrates effective cost control and strong profitability relative to its peers.
- Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 0.86, Usana Health Sciences showcases strong earnings per share.
Assessing Valuation Metrics:
- Price to Earnings (P/E) Ratio: The current P/E ratio of 13.94 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
- Price to Sales (P/S) Ratio: The current P/S ratio of 0.96 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): The company's EV/EBITDA ratio of 5.27 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Delving Into the Significance of Insider Transactions Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
Unlocking the Meaning of Transaction Codes Examining transactions, investors often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Usana Health Sciences's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.